Clinical trials: Retinopathy, Diabetic
Diabetic Retinopathy, Depression
Diabetic Retinopathy as a Marker of Cognitive Dysfunction and Depression
In recent years damage to the nerve fibers in the retina has been experienced as an early sign of complications resulting from type 2 diabetes.
- Conditions
- Diabetic Retinopathy, Depression, Cognitive Impairment, Cognitive Dysfunction
- Trial name
- DIRMA (NCT04610749)
- Where
- Denmark
- Volunteers
- 148 people
- Sponsor
- Region of Southern Denmark
Diabetic Retinopathy, Diabetic Macular Edema
Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema
The DRAGONS study is a non-interventional, prospective study that will 1. characterize disease state biomarker (including cytokines, KKS metabolites, and cell adhesion molecules) levels from aqueous humor of subjects with various…
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Other Retinal Disorders
- Trial name
- DRAGONS (NCT05333055)
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- Greater Houston Retina Research
Diabetic Macular Edema, Diabetic Retinopathy
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Macular edema in diabetes, defined as retinal thickening within two disc diameters of the center of the macula, results from retinal microvascular changes that compromise the blood-retinal barrier, causing leakage of plasma…
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema, Macular Degeneration
- Trial name
- NCT06305416
- Testing
- Ranibizumab 10mg/ml Injection, Lucentis
- Where
- Bangladesh
- Volunteers
- 70 people
- Sponsor
- Incepta Pharmaceuticals Ltd
Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy New Vessels on Disc
The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR)
Commonly know that one of the complications caused by Diabetes Mellitus (DM) is microangiopathy. Microangiopathy in the long term may lead to neuropathy of the corneal nerves.
- Conditions
- Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy New Vessels on Disc, Dry Eye Syndromes
- Trial name
- NCT04000789
- Testing
- Sodium Hyaluronate, Vitamin A, Vitamin E
- Volunteers
- 96 people
- Sponsor
- Dr Cipto Mangunkusumo General Hospital
Diabetic Retinopathy, Diabetic Macular Edema (DME)
AI Prediction of Treatment Response in DME
Diabetic macular edema (DME) is a leading cause of vision loss among individuals with diabetes mellitus. Although intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard treatment for…
- Trial name
- NCT07707856
- Testing
- Artificial Intelligence-Based Imaging Analysis
- Where
- Egypt
- Volunteers
- 1,284 people
- Sponsor
- Benha University
Diabetic Retinopathy
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial
The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, among subjects who completed the 2-year PANORAMA trial (VGFTe-OD-1411) and were…
- Trial name
- VOYAGE (NCT04708145)
- Testing
- Aflibercept Injection
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 41 people
- Sponsor
- Greater Houston Retina Research
Macular Edema
Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.
To evaluate the change in quality of life (NEI VFQ 25) in subjects with DME during the first year of treatment with aflibercept according to the EU Label.
- Trial name
- AQUA (NCT02581995)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- 76 sites in Austria, Canada and 12 more
- Volunteers
- 560 people
- Sponsor
- Bayer
Diabetic Macular Edema
Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema
Currently, diabetic macular edema is treated is through injection of a medications such as off-label bevacizumab, which decreases the swelling in the retina.
- Trial name
- NCT02229175
- Testing
- bevacizumab, PASCAL Endpoint Management (EpM) laser treatment
- Where
- United States
- Sponsor
- University of California, San Francisco
High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
To evaluate the safety and determine the efficacy of PRP monotherapy or combination therapy (pegaptanib 0.3 mg plus PRP) in patients with Type I or Type II diabetes mellitus and with high risk proliferative diabetic retinopathy.
- Conditions
- High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I, Diabetes Mellitus Type II
- Trial name
- NCT01281098
- Testing
- Panretinal Photocoagulation (PRP), Intravitreous injection of pegaptanib
- Where
- Portugal
- Volunteers
- 22 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetes, Diabetic Retinopathy
Genetic Association of Diabetic Retinopathy-1
The primary purpose of the study is to investigate allele frequencies of candidate genes in Chinese diabetic patients with or without known diabetic retinopathy.
- Trial name
- DMR-1 (NCT01298245)
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Age-Related Macular Degeneration, Retinal Vein Occlusion
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
This study was conducted because the FDA requested clinical information on potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium from a 1-year (minimum) post-approval…
- Conditions
- Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
- Trial name
- NCT01573572
- Testing
- pegaptanib sodium injection
- Where
- 4 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetes Mellitus, Type 2, Diabetic Retinopathy
Exploring the Effectiveness of AI Generative Models for Diabetic Patients
We plan to explore the usability of Generative AI-Chatbot for Diabetic Patient
- Conditions
- Diabetes Mellitus, Type 2, Diabetic Retinopathy, Diabetes
- Trial name
- NCT05883072
- Testing
- Exploring AI-Chatbot
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Pakistan Council of Scientific and Industrial Research
Diabetic Retinopathy
Detecting the Influence of Cataract Surgery on the Development of Diabetic Retinopathy in Patients With Diabetes Mellitus Type 2 With and Without Diabetic Retinopathy Using OCT Angiography
Detecting the influence of cataract surgery on the development of diabetic retinopathy in patients with diabetes mellitus type 2 with and without diabetic retinopathy using OCT angiography.
- Trial name
- NCT03571139
- Testing
- Phacoemulsification
- Where
- Jordan
- Volunteers
- 50 people
- Sponsor
- Cairo University
Alzheimer Disease, Alzheimer Dementia
Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease
Because of a shared ontogenic origin, the retina displays similarities to the brain and spinal cord in terms of anatomy, functionality, response to insult, and immunology.
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment, Dementia
- Trial name
- RetAD (NCT03466177)
- Testing
- Non-invasive, multimodal retinal imaging
- Where
- Belgium
- Volunteers
- 320 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Diabetes Mellitus, Obstructive Sleep Apnea
Role of Obstructive Sleep Apnea Syndrome in the Occurrence of Diabetic Retinopathy in Type 2 Diabetes.
Diabetic retinopathy (DR) is the most common visual complication of diabetes. Risk factors for developing DR are diabetes duration, glycemic control, and hypertension .
- Trial name
- NCT03314467
- Testing
- polysomnography
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire Saint Pierre
Diabetic Retinopathy
Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart
Comparing visual acuity measurements (measurements of how well you can see) using a standard ETDRS (Early Treatment Diabetic Retinopathy Study) chart and a handheld ETDRS chart
- Trial name
- NCT01622816
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Julia Haller
Type 1 Diabetes, Diabetic Retinopathy
Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in Denmark
The objective of this study is to clarify the current diabetic status, including development of complications, in a nationwide cohort of type 1 diabetics, who were last examined together in a large study in 1995.
- Trial name
- DCPD1987 (NCT01785667)
- Where
- Denmark
- Volunteers
- 132 people
- Sponsor
- Odense University Hospital
Pain
Intravitreal Injection Site and Perceived Pain
The objective of this study is to explore the perception of pain during intravitreal injection related to the distance of the entry site from the limbus.
- Trial name
- NCT05640895
- Testing
- Intravitreal injection site
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Healthy Adult, Diabetic Retinopathy, DR
The Effect of Different Auditory Types on Visual Evoked Potentials (VEP)
To investigate the effect of different sound types on pattern visual evoked potential (VEP) responses among healthy adults
- Trial name
- NCT07850245
- Where
- Saudi Arabia
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- King Saud University
Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients
Generally, DM is caused by insufficient insulin secretion in the body; however, the other biological mechanisms remain unclear. Long-term illness in patients with DM damages various organs in the body, such as the eyes, kidneys…
- Conditions
- Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation
- Trial name
- NCT06879301
- Testing
- Intravitreal injection of aflibercept 8 mg
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tanta University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.